Sargent Investment Group LLC Has $5.26 Million Position in Abbott Laboratories (NYSE:ABT)

Sargent Investment Group LLC grew its holdings in shares of Abbott Laboratories (NYSE:ABT) by 1.1% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 46,091 shares of the healthcare product maker’s stock after buying an additional 505 shares during the period. Abbott Laboratories makes up 0.9% of Sargent Investment Group LLC’s investment portfolio, making the stock its 29th largest holding. Sargent Investment Group LLC’s holdings in Abbott Laboratories were worth $5,255,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of ABT. Unique Wealth Strategies LLC purchased a new position in shares of Abbott Laboratories during the 2nd quarter valued at about $28,000. Future Financial Wealth Managment LLC purchased a new stake in Abbott Laboratories during the third quarter valued at $31,000. Itau Unibanco Holding S.A. purchased a new stake in Abbott Laboratories during the second quarter valued at $32,000. Valued Wealth Advisors LLC increased its position in Abbott Laboratories by 78.4% during the third quarter. Valued Wealth Advisors LLC now owns 289 shares of the healthcare product maker’s stock valued at $33,000 after acquiring an additional 127 shares during the last quarter. Finally, Ridgewood Investments LLC purchased a new stake in Abbott Laboratories during the second quarter valued at $37,000. 75.18% of the stock is currently owned by institutional investors.

Insider Activity

In other Abbott Laboratories news, CEO Robert B. Ford sold 141,679 shares of the stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $116.41, for a total value of $16,492,852.39. Following the completion of the sale, the chief executive officer now directly owns 220,059 shares in the company, valued at $25,617,068.19. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.10% of the stock is currently owned by insiders.

Abbott Laboratories Stock Down 0.0 %

Abbott Laboratories stock traded down $0.03 during mid-day trading on Thursday, hitting $115.71. The company’s stock had a trading volume of 776,979 shares, compared to its average volume of 5,681,946. The firm’s 50 day moving average is $115.45 and its 200 day moving average is $109.39. The company has a market cap of $200.69 billion, a PE ratio of 35.18, a price-to-earnings-growth ratio of 2.74 and a beta of 0.72. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.60 and a quick ratio of 1.14. Abbott Laboratories has a 52-week low of $96.92 and a 52-week high of $121.64.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Wednesday, October 16th. The healthcare product maker reported $1.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.20 by $0.01. The firm had revenue of $10.64 billion for the quarter, compared to analyst estimates of $10.55 billion. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.99%. The company’s revenue was up 4.9% on a year-over-year basis. During the same quarter last year, the firm posted $1.14 EPS. On average, analysts anticipate that Abbott Laboratories will post 4.67 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 15th. Shareholders of record on Tuesday, October 15th will be paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 1.90%. The ex-dividend date of this dividend is Tuesday, October 15th. Abbott Laboratories’s dividend payout ratio is currently 66.87%.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Oppenheimer began coverage on Abbott Laboratories in a research note on Tuesday, October 8th. They issued an “outperform” rating and a $130.00 price objective for the company. Raymond James restated a “buy” rating and set a $129.00 price target (up previously from $122.00) on shares of Abbott Laboratories in a research note on Monday, October 14th. Royal Bank of Canada upped their price objective on Abbott Laboratories from $125.00 to $130.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 8th. Sanford C. Bernstein lifted their price target on shares of Abbott Laboratories from $133.00 to $138.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Finally, Piper Sandler Companies initiated coverage on shares of Abbott Laboratories in a research report on Thursday, September 19th. They set an “overweight” rating and a $131.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $130.07.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.